<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677597</url>
  </required_header>
  <id_info>
    <org_study_id>CISPEC study</org_study_id>
    <nct_id>NCT02677597</nct_id>
  </id_info>
  <brief_title>Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal
      Squamous Cell Carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Since the date of random to disease progression or any cause of death，the average time is 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cisplatin Combined With S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 75mg/m2 ivgtt d1 S-1 BSA＜1.5 50mg bid，BSA≥1.5 60mg bid po d1-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin Combined With Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin Combined With S-1</intervention_name>
    <arm_group_label>Cisplatin Combined With S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin Combined With Paclitaxel</intervention_name>
    <arm_group_label>Cisplatin Combined With Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven primary thoracic esophageal squamous cell carcinoma

          -  Not suitable for surgery or radio or chemical therapy

          -  Presence of at least one index lesion measurable by CT scan or MRI radiation therapy
             ended at least 4 weeks, but part of the radiation does not as a measurable lesions

          -  18~70 years

          -  PS:0-1

          -  Life expectancy of ≥ 3 months

          -  WBC≥3.5×109/L,ANC≥1.5×109/L, PLT≥100×109/L, Hb≥100g/L

          -  TB ≤ 1.5UNL, ALT/AST ≤ 2.5×UNL

          -  Scr≥60 mL/min

          -  Normal electrocardiogram (ecg)

          -  Can normal oral drugs

          -  Signed written informed consent

        Exclusion Criteria:

          -  Breast-feeding or pregnant women, no effective contraception if risk of conception
             exists

          -  Chronic diarrhea, enteritis, intestine obstruction which are not under control

          -  Esophageal obstruction cannot eat liquid completely, esophagus have deep ulcer
             perforation or hematemesis; Esophageal cancer common complications such as anastomotic
             leakage, serious lung complications, etc.

          -  A second primary tumor (except skin basal cell carcinoma)

          -  The original serious heart disease, including: higher risk of congestive heart
             failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe
             valvular heart disease, and resistant hypertension

          -  With uncontrol nerve, mental illness or mental disorders, compliance is poor, can't
             cooperate with accounts and response to treatment; Primary brain tumors or - CNS
             metastases illness did not get a control, has obvious cranial hypertension or nerve
             mental symptoms

          -  With bleeding tendency

          -  Has inherited bleeding evidence of physical or blood coagulation disorder

          -  With clear chemotherapy drug allergy

          -  Other researchers believe that patients should not participate in this testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang J Hua, PD</last_name>
    <phone>13916619284</phone>
    <email>changjianhua@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang J hua, PD</last_name>
      <phone>13916619284</phone>
      <email>changjianhua@163.com</email>
    </contact>
    <investigator>
      <last_name>Chang J hua, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

